RECURSION PHARMACEUTICALS, INC. Notes Payable, Noncurrent
RECURSION PHARMACEUTICALS, INC. (RXRX) had Notes Payable, Noncurrent of $1.07 million as of 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermNotesPayable · last filed 2024-05-09
- 2024-03-31: Notes Payable, Noncurrent $1.07M.
- 2023-12-31: Notes Payable, Noncurrent $1.10M.
- 2023-09-30: Notes Payable, Noncurrent $1.13M.
- 2023-06-30: Notes Payable, Noncurrent $1.16M.
| Period end | Notes Payable, Noncurrent |
|---|---|
| 2024-03-31 | $1.07M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.10M 10-Q · filed 2024-05-09 |
| 2023-09-30 | $1.13M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.16M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.18M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $536.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $561.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $586.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $610.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $633.00K 10-K · filed 2023-02-27 |
| 2021-09-30 | $656.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $9.42M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $10.34M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $11.41M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |